Auris Medical AG
Falknerstrasse 4
Basel
4001
Tel: 41-61-201-13-50
Fax: 41-61-201-13-51
Website: http://www.aurismedical.com/
181 articles about Auris Medical AG
-
Auris Medical to Redomicile Holding Company from Switzerland to Bermuda
1/29/2019
Auris Medical Holding AG announced its intention to relocate the Company's domicile from Zug, Switzerland to Hamilton, Bermuda.
-
Auris Medical Announces Publication of New Data Highlighting the Role of Betahistine in Promoting the Restoration of Forgotten Memories in Mice and Healthy Volunteers
1/23/2019
Auris Medical Holding AG today highlighted the advance publication of an article demonstrating that betahistine promotes the retrieval of forgotten memories in mice and in healthy human volunteers.
-
Auris Medical Provides Update on Intranasal Betahistine Programs
1/15/2019
Closes acquisition of Orphan Drug Designation for betahistine for the treatment of obesity associated with Prader-Willi syndrome (PWS)
-
Auris Medical Announces Acquisition of Orphan Drug Designation and Secures Rights to In-License Additional Patents Related to Betahistine
12/6/2018
Acquires Orphan Drug Designation for betahistine for the treatment of obesity associated with Prader-Willi syndrome (PWS)
-
Auris Medical Announces Results of Pre-IND Meeting With FDA For AM-201 Program in Olanzapine-Induced Weight Gain
11/20/2018
Auris Medical Holding AG today announced the results of its pre-Investigational New Drug (pre-IND) meeting with the United States Food & Drug Administration (FDA), where the FDA addressed the Company's questions and provided guidance on its AM-201 program with intranasal betahistine for the prevention of olanzapine-induced weight gain.
-
Auris Medical Reports Third Quarter 2018 Financial Results and Provides Business Update
11/15/2018
Positive outcomes from second Phase 1 trial with intranasal betahistine
-
Auris Medical to Report Third Quarter 2018 Financial Results and Provide Business Update on Thursday, November 15, 2018
11/8/2018
Auris Medical Holding AG today announced that it will provide a business update and report its financial results for the third quarter of 2018 on Thursday, November 15, 2018.
-
Auris Medical Announces Positive Results From Second Phase 1 Clinical Trial With Intranasal Betahistine
10/17/2018
Bioavailability significantly higher than with oral administration
-
Auris Medical Receives FDA Guidance at Type C Meeting for AM-111 in the Treatment of Sudden Sensorineural Hearing Loss
9/7/2018
Auris Medical Holding AG announced today feedback from a Type C meeting with the U.S. Food and Drug Administration (FDA) related to the development plan and regulatory pathway for AM-111, its investigational treatment for sudden sensorineural hearing loss.
-
Auris Medical Reports Second Quarter 2018 Financial Results and Provides Business Update
8/15/2018
Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, today announced financial results for the second quarter ended June 30, 2018 and provided a business update.
-
Shares of Switzerland-based Auris Medical Holding AG shot up nearly 10 percent Monday after the company announced it received clearance to begin a new Phase III trial for AM-111, the company’s investigational treatment for acute inner ear hearing loss.
-
Auris Health Unveils the FDA-Cleared Monarch Platform, Ushering in a New Era of Medical Intervention
3/23/2018
Company’s First Application of Its Innovative Flexible Robotics Platform Is Bronchoscopy
-
Auris Medical has gone down swinging again in attempting to develop a treatment for tinnitus after it announced its Phase III trial failed to meet endpoints.
-
Auris Medical Reports New Data Highlighting Superior Bioavailability of AM-125 Compared to Oral Betahistine
2/7/2018
The results show markedly higher blood plasma concentrations when betahistine administered intranasally rather than orally.
-
Auris Medical Announces Pricing of $5.5M Registered Direct Offering
1/30/2018
The Company also agreed to issue warrants to purchase up to an aggregate of 7,499,999 common shares to the investors in a concurrent private placement.
-
Auris Medical Provides Update on AM-111 Development Program
1/4/2018
Further analyses on the basis of the full data set provide additional confirmation of and support for AM-111's otoprotective effects in the profound acute hearing loss subpopulation.
-
Auris Medical to Provide Update on Its AM-111 Hearing Loss Program on Thursday, January 4, 2018
12/28/2017
Following the announcement, Auris Medical's management team will host a live conference call and webcast at 8:00 AM ET.
-
AM-111 failed to meet its primary endpoint, although the company is putting a positive spin on it by noting it was effective in a subpopulation.
-
Auris Medical Reports Third Quarter 2017 Financial Results and Provides Business Update
11/28/2017
Cash and cash equivalents at September 30, 2017, totaled CHF 20.2 million.
-
Auris Medical to Report Third Quarter 2017 Financial Results and Provide Business Update on Tuesday, November 28, 2017
11/21/2017
Following the announcement, Auris Medical's management team will host a live conference call and webcast at 8:00 am Eastern Time.